Fran Gregory News Today

In 2024, the Asembia Specialty Pharmacy Summit celebrated 20 years and speakers highlighted the conversations around improving access and affordability taking place at the meeting.

Fran Gregory discusses the challenges posed by rising drug costs and emphasized that optimizing the use of biosimilars, which are entering the market at much lower prices than their reference products.

There are multiple levers that need to be pulled to allow biosimilars to come to market more broadly in the US, explained Fran Gregory, PharmD, MBA, vice president of emerging therapies, Cardinal Health.

In a review, investigators focused on ranibizumab (Lucentis; Genentech), aflibercept (Eylea; Regeneron), and bevacizumab (Avastin; Genentech) as growth opportunities in the biosimilar space.

Biosimilars cost on average 50% less than biologic drugs, which could save patients with things like cancer and MS, a lot of money

Biosimilars cost on average 50% less than biologic drugs, which could save patients with things like cancer and MS, a lot of money

Biosimilars cost on average 50% less than biologic drugs, which could save patients with things like cancer and MS, a lot of money

Study reveals impact of dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability DUBLIN, Ohio, Feb. 29, 2024...

MOUNT ORAB, Ohio – Mount Orab Police Department were dispatched to two reported burglaries on Jan. 23 and Jan. 25 that resulted in an arrest.

The biosimilars landscape is set to witness significant growth, particularly in therapeutic areas like ophthalmology and immunology, with a focus on blockbuster biologics like Humira, Stelara, and Eylea.